.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
SELECT was a landmark cardiovascular-outcomes trial evaluating semaglutide 2.4 mg weekly in adults with established cardiovascular disease and overweight or obesity who did not have diabetes. More than 17,000 participants were followed for nearly four years. Semaglutide reduced the risk of major adverse cardiovascular events compared with placebo, extending the evidence base for GLP-1 receptor agonists beyond glucose lowering and into obesity-related cardiovascular risk reduction. For internists, the implication is important: obesity can be treated as a chronic disease with pharmacologic tools that may influence multiple risk pathways, not simply body weight. The magnitude of benefit cannot be assumed to be identical in every patient, and treatment remains dependent on appropriate selection, tolerability, access and long-term adherence. Gastrointestinal adverse effects are common, and therapy is most effective when integrated with nutrition, physical activity and management of other risk factors. SELECT therefore supports a more cardiometabolic approach to obesity care in which weight, blood pressure, glycemia, lipids and cardiovascular risk are addressed together.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
SELECT was a landmark cardiovascular-outcomes trial evaluating semaglutide 2.4 mg weekly in adults with established cardiovascular disease and overweight or obesity who did not have diabetes. More than 17,000 participants were followed for nearly four years. Semaglutide reduced the risk of major adverse cardiovascular events compared with placebo, extending the evidence base for GLP-1 receptor agonists beyond glucose lowering and into obesity-related cardiovascular risk reduction. For internists, the implication is important: obesity can be treated as a chronic disease with pharmacologic tools that may influence multiple risk pathways, not simply body weight. The magnitude of benefit cannot be assumed to be identical in every patient, and treatment remains dependent on appropriate selection, tolerability, access and long-term adherence. Gastrointestinal adverse effects are common, and therapy is most effective when integrated with nutrition, physical activity and management of other risk factors. SELECT therefore supports a more cardiometabolic approach to obesity care in which weight, blood pressure, glycemia, lipids and cardiovascular risk are addressed together.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
